*All macular oedema events were resolved.²
 

Transient decreases in heart rate and AV conduction delays may occur upon initiation of VELSIPITY^1,2

• Initiation of VELSIPITY may result in a transient decrease in heart rate and AV conduction delays 
• Most events of bradycardia were mild and asymptomatic
• Bradycardia was reported in 1.5% of patients treated with VELSIPITY on the day of treatment initiation, and in 0.4% of patients treated with VELSIPITY on Day 2 
• Of the 9 events across ELEVATE UC 52 and ELEVATE UC 12, 8 were reported on Day 1 and the remaining event on Day 2

Macular oedema¹

• Risk of macular oedema is higher in patients with diabetes mellitus, uveitis or underlying/co-existing retinal disease
• It is recommended that these patients undergo an ophthalmic evaluation prior to treatment initiation with Velsipity and have follow-up evaluations while receiving therapy.

Cardiac contraindications¹

• VELSIPITY is contraindicated in patients with certain pre-existing cardiac abnormalities 
  • Patients in the last 6 months who experienced myocardial infarction, unstable angina pectoris, stroke, transient ischaemic attack, decompensated heart failure requiring hospitalisation, or New York Heart Association Class III or Class IV heart failure. Patients with history or presence of Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sinoatrial block, unless patient has a functioning pacemaker¹